Redwire to Test 3D Bioprinted Liver Tissue in Space, Reinforcing the Company’s Focus on Transforming the Future of Organ Transplantation on Earth

Rhea-AI Summary

Redwire (NYSE: RDW) is launching a groundbreaking experiment to the International Space Station (ISS) to analyze the effects of microgravity on tissue bioprinting and culturing. In collaboration with Wake Forest Institute of Regenerative Medicine, Redwire will culture 36 bioprinted vascularized liver tissue constructs in space. This initiative aims to determine if liver cells bioprinted on Earth can form functioning blood vessels in microgravity, potentially addressing the global organ shortage.

Redwire has made significant progress in space biotech, successfully bioprinting human knee meniscus and heart tissue samples in space. The company is also launching four drug manufacturing experiments in its PIL-BOX system, marking its third spaceflight mission in 10 months. These experiments will launch to the ISS aboard the Northrop Grumman NG-21 cargo resupply mission in early August 2024.

Positive

• Launching experiment to analyze effects of microgravity on tissue bioprinting and culturing
• Successfully bioprinted human knee meniscus and heart tissue samples in space
• Launching four drug manufacturing experiments in PIL-BOX system
• Third spaceflight mission for PIL-BOX in 10 months
• Potential to address global organ shortage through space-based bioprinting

Negative

• None.

Biomedical Research Analyst

As a Biomedical Research Analyst, I find Redwire's latest space bioprinting experiment to be a significant step forward in regenerative medicine. The company's focus on bioprinting vascularized liver tissue constructs in microgravity is particularly noteworthy. Here's why:

• Vascularization is important for the viability of bioprinted tissues, as it allows for nutrient and oxygen delivery. If successful, this experiment could pave the way for creating more complex, functional tissues in space.
• The use of Redwire's Multi-Use Variable-Gravity Platform demonstrates the company's commitment to developing specialized equipment for space-based biomedical research.
• This experiment builds upon Redwire's previous successes in bioprinting a human knee meniscus and heart tissue samples in space, showing a clear progression in their capabilities.

The potential implications of this research are far-reaching. If Redwire can consistently produce functional tissues in microgravity, it could revolutionize organ transplantation and address the global organ shortage. However, it's important to note that we're still in the early stages and significant challenges remain in scaling up from tissue samples to full organs.

Additionally, Redwire's concurrent launch of four drug manufacturing experiments using their PIL-BOX system is indicative of their broader strategy in space biotechnology. The focus on optimizing performance and demonstrating repeatability is important for establishing the reliability of space-based drug manufacturing processes.

While the potential is exciting, investors should be aware that the path from research to commercialization in this field is long and complex, requiring extensive testing and regulatory approvals before any products can reach the market.

Space Industry Analyst

From a space industry perspective, Redwire's latest initiatives underscore the growing importance of microgravity research in advancing terrestrial medical solutions. Here are key points to consider:

• Redwire is positioning itself as a leader in the emerging field of space-based biotech, leveraging the unique microgravity environment of the ISS for both tissue engineering and pharmaceutical research.
• The company's partnership with the Wake Forest Institute of Regenerative Medicine and support from the ISS National Lab and NASA demonstrate its ability to collaborate with top-tier research institutions and secure critical backing from space agencies.
• The frequent flight missions of the PIL-BOX system (three in 10 months) indicate a rapid iteration cycle, which is important for advancing space-based technologies and processes.

Redwire's focus on developing a suite of space-based hardware for bioprinting and drug manufacturing experiments could potentially create a new market segment within the space economy. If successful, this could lead to increased demand for space access and on-orbit facilities dedicated to biomedical research and production.

However, investors should be mindful that the space biotech sector is still in its infancy. While Redwire appears to be making significant strides, the commercial viability of these technologies remains to be proven. The company will need to demonstrate not only scientific success but also a clear path to profitability in this novel field.

The upcoming NG-21 cargo resupply mission in August 2024 will be a critical milestone to watch, as it will provide more data on the repeatability and reliability of Redwire's space-based biotech processes.

Financial Analyst

From a financial perspective, Redwire's latest announcement showcases its strategic positioning in the high-potential space biotech market. Here's my analysis:

• Diversification: By expanding into bioprinting and pharmaceutical research, Redwire is diversifying its revenue streams beyond traditional space infrastructure, potentially reducing risk and opening new growth avenues.
• Intellectual Property: Successful experiments could lead to valuable patents in space-based bioprinting and drug manufacturing, creating long-term value for the company.
• Partnerships: Collaborations with institutions like Wake Forest and support from NASA and the ISS National Lab enhance Redwire's credibility and may lead to future funding opportunities or commercial partnerships.
• Market Potential: The global organ transplant market is projected to reach $26.5 billion by 2028. If Redwire can capture even a small portion of this market with its space-based solutions, it could significantly impact its future revenues.

However, investors should consider several factors:

• R&D Costs: Space-based research is expensive and it may take years before these initiatives translate into commercial products, potentially impacting short-term profitability.
• Regulatory Hurdles: The path to approval for space-manufactured medical products will likely be complex and time-consuming, adding uncertainty to the timeline for potential returns.
• Competition: As the potential of space-based biotech becomes more apparent, Redwire may face increased competition from both established space companies and biotech firms entering the market.

While Redwire's initiatives in space biotech are promising, they represent a long-term play. Investors should carefully weigh the potential rewards against the risks and uncertainties inherent in this cutting-edge field. The company's ability to manage costs, secure additional funding and progress towards commercialization will be critical factors to monitor in the coming years.

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it is launching an experiment to the International Space Station (ISS) that will analyze the effects of microgravity on tissue bioprinting and culturing. In partnership with Wake Forest Institute of Regenerative Medicine (WFIRM), Redwire will culture 36 bioprinted vascularized liver tissue constructs inside the company’s Multi-Use Variable-Gravity Platform on the ISS to determine if liver cells bioprinted on Earth can properly form functioning blood vessels in microgravity.

The investigation reinforces Redwire’s focus on improving space bioprinting techniques with human tissue samples with the goal of eventually bioprinting full-scale organs, which could offer a promising solution for addressing the world’s organ shortage. Redwire has made significant progress on its space biotech initiatives in the last 12 months, successfully bioprinting a human knee meniscus and heart tissue samples in space.

Additionally, Redwire is launching four drug manufacturing experiments in the company’s Pharmaceutical In-space Laboratory Bio-crystal Optimization eXperiment (PIL-BOX) system, marking the third spaceflight mission for PIL-BOX in the last 10 months. Redwire aims to use these frequent flight missions to optimize the system’s performance and demonstrate repeatability.

“Redwire is building tremendous momentum with our space biotech capabilities as we engage with new customers and partners to identify critical targets for breakthrough research and increase throughput of bioprinting and drug manufacturing experiments using our space-based suite of hardware,” said John Vellinger, President of In-Space Industries at Redwire. “We are grateful for our strong partnership with Wake Forest Institute of Regenerative Medicine along with crucial support from the ISS National Lab and NASA. We’re eager to build on our recent trailblazing results and further validate our microgravity research and manufacturing capabilities that could one day translate to life-saving medical products and drugs.”

WFIRM’s liver tissue experiment is being conducted with support from the ISS National Laboratory as part of NASA’s Vascular Tissue Challenge.

Redwire aims to continue launching PIL-BOX investigations on upcoming commercial resupply missions. Prior PIL-BOX experiments have produced high-quality uniform crystals that could be used in antiviral and antifungal applications.

These newest experiments will launch to the ISS aboard the Northrop Grumman NG-21 cargo resupply mission scheduled for early August 2024.

About Redwire

Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 700 employees working from 14 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit redwirespace.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730646683/en/

Emily Devine

Emily.Devine@redwirespace.com

305-632-9137



OR



Investors:

investorrelations@redwirespace.com

904-425-1431

Source: Redwire Corporation

FAQ

What is Redwire (RDW) launching to the International Space Station?

Redwire is launching an experiment to analyze the effects of microgravity on tissue bioprinting and culturing, specifically 36 bioprinted vascularized liver tissue constructs.

What is the goal of Redwire's (RDW) liver tissue experiment in space?

The goal is to determine if liver cells bioprinted on Earth can properly form functioning blood vessels in microgravity, potentially leading to bioprinting full-scale organs to address the world's organ shortage.

When is Redwire's (RDW) space bioprinting experiment scheduled to launch?

The experiment is scheduled to launch to the ISS aboard the Northrop Grumman NG-21 cargo resupply mission in early August 2024.

What other bioprinting achievements has Redwire (RDW) accomplished in space?

Redwire has successfully bioprinted a human knee meniscus and heart tissue samples in space within the last 12 months.